Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

It can vary depending on your sleeping pattern and schedule, but generally, the worst time to nap is during the late ...

Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

By Dr. Jaisingh Rajput, MD  Sleep is essential for heart health, but millions of Americans unknowingly suffer from sleep ...

People with certain types of long-term sleep disorders feel extremely tired during the day, a condition known as excessive daytime sleepiness (EDS). There are many medicines that work in different ...

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

UC San Francisco study finds women over 80 who experience increased daytime sleepiness face twice the risk of developing dementia.

could result in greater daytime sleep needs. Inflammation and vascular risk may [also] be contributing factors. Disrupted sleep patterns and excessive sleep are linked to increased inflammation and ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Given sleep’s profound impact on well-being, unexplained daytime fatigue and disrupted sleep patterns necessitate a ...

If you have a long-term sleep disorder that causes excessive daytime sleepiness (EDS), you may need to take medicines to manage your symptoms. The different medicines available for these ...